You just read:

BerGenBio to Present New NSCLC and AML Clinical Data and Biomarker Data From Phase II Development Programme With Selective AXL Inhibitor Bemcentinib at ASCO 2019

News provided by

BerGenBio ASA

May 15, 2019, 18:33 ET